Advances in psoriasis treatment: Experts comment on recent developments

摘要

The treatment of psoriasis is changing, thanks to a growing understanding that it is a disease of systemic inflammation.1'2 In this regard, drug candidates targeting the interleukin-23 (IL-23) and type-17 helper (IL-23/Thl7) T-cell pathway appear particularly promising, offering high rates of clearance or near-clearance of psoriatic lesions.3"5 Along with their role in treating psoriasis, ustekinumab (Stelara, Janssen) and the tumor necrosis factor-alpha (TNF-alpha) inhibitors, in particular, are helping physicians target cardiovascular disease, one of the many known comorbidities of psoriasis.